Insider Buying: OPKO Health (OPK) CEO Acquires $44,200.00 in Stock

Share on StockTwits

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 10,000 shares of the business’s stock in a transaction on Friday, June 15th. The shares were acquired at an average price of $4.42 per share, for a total transaction of $44,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $13,564,763.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, June 18th, Phillip Md Et Al Frost purchased 14,299 shares of OPKO Health stock. The shares were acquired at an average price of $4.34 per share, for a total transaction of $62,057.66.
  • On Monday, June 11th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The shares were acquired at an average price of $4.22 per share, for a total transaction of $42,200.00.
  • On Wednesday, June 6th, Phillip Md Et Al Frost purchased 30,000 shares of OPKO Health stock. The shares were acquired at an average price of $4.05 per share, for a total transaction of $121,500.00.
  • On Thursday, May 31st, Phillip Md Et Al Frost purchased 3,900 shares of OPKO Health stock. The shares were acquired at an average price of $3.76 per share, for a total transaction of $14,664.00.
  • On Friday, May 25th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The shares were acquired at an average price of $3.70 per share, for a total transaction of $37,000.00.
  • On Wednesday, May 23rd, Phillip Md Et Al Frost purchased 40,000 shares of OPKO Health stock. The shares were acquired at an average price of $3.73 per share, for a total transaction of $149,200.00.
  • On Monday, May 21st, Phillip Md Et Al Frost bought 90,000 shares of OPKO Health stock. The stock was purchased at an average price of $3.82 per share, for a total transaction of $343,800.00.
  • On Friday, May 18th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $4.04 per share, for a total transaction of $404,000.00.
  • On Friday, May 4th, Phillip Md Et Al Frost bought 26,000 shares of OPKO Health stock. The stock was purchased at an average price of $3.14 per share, for a total transaction of $81,640.00.
  • On Wednesday, May 2nd, Phillip Md Et Al Frost bought 50,330 shares of OPKO Health stock. The stock was purchased at an average price of $3.15 per share, for a total transaction of $158,539.50.

OPKO Health traded down $0.08, hitting $4.71, during trading hours on Thursday, Marketbeat.com reports. 148,306 shares of the company traded hands, compared to its average volume of 4,236,892. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.03. OPKO Health has a one year low of $2.66 and a one year high of $7.25. The stock has a market cap of $2.43 billion, a PE ratio of -16.28 and a beta of 1.67.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. OPKO Health had a negative return on equity of 8.76% and a negative net margin of 31.27%. The business had revenue of $254.90 million for the quarter, compared to analysts’ expectations of $236.90 million. During the same period last year, the business earned ($0.06) EPS. The business’s revenue was down 4.3% on a year-over-year basis. sell-side analysts forecast that OPKO Health will post -0.27 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the business. BDO Wealth Advisors LLC increased its position in shares of OPKO Health by 12,000.0% during the 1st quarter. BDO Wealth Advisors LLC now owns 60,500 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 60,000 shares during the last quarter. Xact Kapitalforvaltning AB increased its position in shares of OPKO Health by 58.2% during the 1st quarter. Xact Kapitalforvaltning AB now owns 57,921 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 21,300 shares during the last quarter. Millennium Management LLC increased its position in shares of OPKO Health by 95.6% during the 1st quarter. Millennium Management LLC now owns 2,178,877 shares of the biotechnology company’s stock valued at $6,907,000 after purchasing an additional 1,065,216 shares during the last quarter. ETF Managers Group LLC purchased a new stake in shares of OPKO Health during the 1st quarter valued at $604,000. Finally, UBS Group AG increased its position in shares of OPKO Health by 13.1% during the 1st quarter. UBS Group AG now owns 1,941,938 shares of the biotechnology company’s stock valued at $6,156,000 after purchasing an additional 224,392 shares during the last quarter. Institutional investors and hedge funds own 23.81% of the company’s stock.

A number of brokerages recently issued reports on OPK. BidaskClub upgraded OPKO Health from a “hold” rating to a “buy” rating in a report on Friday, June 15th. Zacks Investment Research cut OPKO Health from a “buy” rating to a “hold” rating in a report on Friday, May 25th. ValuEngine upgraded OPKO Health from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Barrington Research reiterated a “buy” rating and issued a $7.00 target price on shares of OPKO Health in a report on Wednesday, May 9th. Finally, JPMorgan Chase & Co. cut OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price on the stock. in a report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.21.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply